- Noxopharm drug identified as potential brain/spinal cord injury preventative
- First-in-class drug to hasten rehabilitation from brain and spinal cord injury
- Made possible because of NOX66 drug delivery platform
- UNSW assisting in pre-clinical studies.
Sydney, 15 March 2017: Noxopharm Ltd (ASX:NOX) today unveils the first of its non-oncology drug pipeline, having entered into a research agreement with the University of New South Wales (UNSW) to develop a unique and highly sought preventative treatment for damage to the central nervous system. This includes stroke and spinal injury, and potentially a wide range of neurodegenerative diseases.
For further information please download PDF attached:
Download this document
